• Taisho introduces a minoxidil booster developed by Applied Biology to boost the effectiveness of minoxidil in patients with androgenetic alopecia who are unresponsive to minoxidil

• Minoxidil sulfotransferase enzyme booster (SULT1A1) was acquired by Jupiter Wellness in an asset acquisition comprising issued patents, patent applications, products, clinical trial results and license agreements of Applied Biology

Check out Jupiter Wellness, Inc. (NASDAQ: JUPW) at www.topnasdaq.com to see why it is undervalued

– JUPW Just Acquired a $3 Million Business and Launched a $5 Million Share Buyback

– Featured on CNN, ABC, CBS, Bloomberg, Vogue and Forbes

– Developer of CBD-based treatments for multiple skincare applications.

– New e-commerce and marketing team with experienced industry veterans.

– JW-300 treatment Demonstrated effectiveness in developing burns (sunburn) in a clinical trial.

– Acquisition of Ascent Clinical Research adding $3 million in annual revenue plus contribution to EBITDA.

– Exclusive worldwide rights to patented anti-shark technologies.

– A new combined treatment with cannabidiol and aspartame significantly reduces the ISGA score in atopic dermatitis.

– Exclusive worldwide rights to unique formulas addressing Jellyfish and Man O’ War Stings, Sea Lice and Swimmer’s Itch with 4 patents pending.

– Clinical trial of JW-200 for the treatment of actinic keratosis.

– $5.0 million share buyback program.

Recent news:

JUPW announces that Taisho Pharmaceutical has entered into a licensing agreement for Jupiter Wellness minoxidil booster for the Japanese market.

Minoxidil is the only topical medication approved by the US FDA for the treatment of common hair loss (androgenetic alopecia). Although there are racial and geographic differences, minoxidil is clinically effective in 30-40% of patients. Applied Biology scientists have found that the effectiveness of minoxidil depends on the enzyme minoxidil sulfotransferase (also called SULT1A1) present in hair. After this breakthrough discovery, Applied Biology scientists developed a new minoxidil adjuvant therapy, minoxidil sulfotransferase enzyme booster (SULT1A1), which has been shown in clinical trials to increase the effectiveness of minoxidil (Dhurat R , Daruwalla S, Pai S, Kovacevic M, McCoy J, Shapiro J, Sinclair R, Vano-Galvan S, Goren A). Minoxidil Sulfotransferase Enzyme (SULT1A1) Booster Significantly Improves Response to Topical Minoxidil for Hair Regrowth (J Cosmet Dermatol. 2022 Jan;21(1):343-346. doi: 10.1111/jocd.14299. Epub 2021 Jun 25. PMID: 34133836).

In an effort to help hair loss patients in Japan, Taisho Pharmaceutical, the largest manufacturer of minoxidil and a leader in hair therapies in Japan, now plans to support hair loss patients with this breakthrough adjuvant therapy. with topical minoxidil.

About Taisho Pharmaceutical

Founded in 1912, Taisho Pharmaceutical Co., Ltd. (https://www.taisho.co.jp/global/), headquartered in Tokyo, Japan, is a pharmaceutical company that develops both Rx and OTC pharmaceuticals. Taisho has a strong presence in the OTC categories, selling #1 in Japan and #7 in the world. Taisho offers various products that are well-known and widely accepted by consumers. RiUP is one such famous brand, and as the first Minoxidil hair loss product in Japan, it has more than 80% market share in Japan. Taisho continuously aims to innovate more to improve consumers’ health.

About JUPW:

Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading developer of cannabidiol (CBD) therapeutic and medical wellness products. The JUPW clinical pipeline of prescription CBD-enhanced skin care therapeutics addresses indications such as eczema, burns, herpetic cold sores, and skin cancer. JUPW generates revenue from a growing line of exclusive over-the-counter skincare products, including its flagship CaniSun™ sunscreen and other wellness brands. JUPW has built a portfolio of award-winning wellness brands including CaniSun, fitCBD, Jack, Wellness CBD 1937, Black Belt CBD and Felix Ambrosia, as well as prescription therapeutics such as Photosil which have been featured in numerous media outlets including the Today Show, CNN, ABC, CBS, Animal Planet, AdWeek, Bloomberg, The Washington Post, Vogue, BuzzFeed and Forbes. As JUPW continues to expand portfolio of clinically tested, science-backed wellness, over-the-counter and prescription products, new marketing team poised to drive revenue

The results demonstrate the potential of JW-300 as a prescription or over-the-counter topical cream to help prevent sunburn and its consequences, including skin cancer.

On April 27, JUPW announced that it had entered into an asset purchase agreement with Ascent Clinical Research, Inc. whereby it acquired certain clinical assets, including clinical trial research contracts worth $3 million. dollars in annual revenue for a purchase price of 5% future net revenue royalties. generated by assets. This asset purchase agreement adds immediate revenue to JUPW in Q2 2022 and positively contributes to EBITDA with no upfront payment or stock acquisition cost.

Watch the Discovery Channel videos on anti-shark technology here: https://youtu.be/Hqp04gdAXyk and here: https://youtu.be/PM0YTlbx1qg

On April 7, JUPW announced the upcoming launch of CaniSun for Shark Defense™, the latest addition to the company’s line of reef-friendly sunscreens. Through a licensing agreement with Shark Defense Technologies LLC, the leading researcher in chemical, electrochemical and magnetic shark repellents, JUPW owns the exclusive worldwide rights to the patents, formulas and production methods of the shark repellent technologies. for use in sunscreen and skin care products.

On April 6, JUPW announced the publication of the results of a clinical study to investigate the safety and efficacy of JW-100, its proprietary lotion formulation for the treatment of atopic dermatitis (eczema) in the Journal of Cosmetic. Dermatology, Vol. 21, number 4, April 2022, pages: 1647-1650.

On April 5, JUPW announced the launch of NoStingz, an exclusive line of sunscreens designed to protect against jellyfish and man-of-war stings, sea lice and swimmer’s itch while continuing to protect the skin. ocean lovers against UVA/UVB in a range of SPF. JUPW has signed a licensing agreement with Shark Defense Technologies for exclusive worldwide intellectual property rights to formulas and production methods for jellyfish protective compounds, including 4 patents pending. The agreement provides for future collaboration to develop and refine additional formulas.

To learn more about the JUPW NoStingz product or to purchase, visit: https://canisun.com/shop/nostingz-your-barrier-of-protection-from-sun-sea/

For more information about Jupiter Wellness, Inc. (JUPW), visit www.jupiterwellnessinc.com.

DISCLAIMER: Products mentioned are THC-free and/or Farm Bill 2018 compliant.

CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news delivery service provider. CAP/FPS/CA is NOT affiliated in any way with any company mentioned herein. CAP/FPS/CA is a news delivery solutions provider and is NOT a registered broker/dealer/analyst/advisor, does not hold any investment license and may NOT sell, offer to sell or offer to buy titles. CAP/FPS/CA’s market updates, news alerts and company profiles are NOT a solicitation or recommendation to buy, sell or hold any securities. The content of this release is intended for informational purposes only and should NEVER be construed or construed as research material. All readers are strongly urged to conduct their own research and due diligence and to consult with a licensed financial professional before considering any level of equity investment. All material included here is republished content and details that have been previously released by the companies mentioned in this release or the opinion of the author. CAP/FPS/CA is not responsible for the investment decisions of its readers or subscribers. Investors are warned that they may lose some or all of their investment when investing in stocks. CAP/FPS/CA was compensated $500 by a third party for the distribution of this article.

Disclaimer/Safe Harbor:

These press releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. Statements reflect the Company’s current beliefs regarding future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, failure to meet deadlines or performance requirements of the companies’ contracts, the companies’ liquidity condition, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive prices. In light of these uncertainties, the forward-looking events discussed in this press release may not occur.

Media Contact
Company Name: Jupiter Wellness, Inc.
Contact person: Brian John, CEO
E-mail: Send an email
Call: 561 244 7100
Address:725 North Highway A1A, Suite C-106
Town: Jupiter
State: FL 33477
Country: United States
Website: https://jupiterwellness.com/